We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subc... Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 6.205 | 20.2249022164 | 30.68 | 38.025 | 29.1 | 908423 | 34.83906519 | CS |
| 4 | -2.145 | -5.49577248271 | 39.03 | 39.195 | 29.1 | 720594 | 33.9065132 | CS |
| 12 | -9.985 | -21.3036057179 | 46.87 | 50.56 | 29.1 | 558768 | 38.49219976 | CS |
| 26 | -12.105 | -24.7091243111 | 48.99 | 63.5 | 29.1 | 509905 | 45.40936145 | CS |
| 52 | -30.715 | -45.4363905325 | 67.6 | 72.29 | 29.1 | 495966 | 48.58413176 | CS |
| 156 | 15.385 | 71.5581395349 | 21.5 | 72.29 | 14.19 | 457945 | 42.56114952 | CS |
| 260 | 15.385 | 71.5581395349 | 21.5 | 72.29 | 14.19 | 457945 | 42.56114952 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
